Boonen, A, Verduyckt, J, Taelman, V, Sileghem, A, ...
Verduyckt, J, Taelman, V, Sileghem, A, ...
An evaluation of foot problems in rheumatoid arthritis (RA) patients (2005)
Verduyckt, J, Taelman, V, Sileghem, A, ...
Corluy, L, Veys, E M, De Clerck, L, Peretz, A, ...
OBJECTIVES: To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. METHODS: Patients...
Durez, P., Corluy, L., Veys, E. M., De Clerck, L., Peretz, A., ...
Objectives. To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. Methods. Patients...
Durez, P., Corluy, L., Veys, E. M., Clerck, L. De, Peretz, A., ...
Objectives. To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. Methods. Patients...
Timing of DAS28 in infliximab therapy: reply (2005)
Durez, P., Corluy, L., Veys, E., De Clerck, L., Peretz, A., ...
Timing of DAS28 in infliximab therapy: reply (2005)
Durez, P., Corluy, L., Veys, E., De Clerck, L., Peretz, A., ...